One of the highest priorities of the Simmons Cancer Center is to efficiently translate scientific discoveries to the clinic in order to reduce cancer morbidity and mortality. U.T. Southwestem has a long tradition of excellence in the basic sciences and with the recent organization of well-defined Cancer Center programs, institutional scientists are responsible for some of the most important recent advances in translatable cancer biology. Early phase Investigator-initiated translational research trials require significant regulatory, data management and research nursing resources that are not always available through traditional mechanisms in a timely fashion. Protocol-specific research support provides a mechanism for rapidly translating institutional cancer science to the clinic. These funds are intended to support the programmatic priorities of the Simmons Cancer Center. Criteria used to assess suitability for Protocol-Specific Research support include: 1. Investigator-initiated feasibility/Phase I or pilot trial with exceptional scientific merit 2. The trial must meet one or more of the following criteria: a. The agent or concept to be tested is a product of U.T. Southwestern preclinical science. b. The trial will generate data required for external peer-reviewed funding or for development into a larger, multi-institutional phase II or III trial. c. The trial promotes significant interaction between basic and clinical scientists to achieve important correlative objectives. Priorities for this funding are communicated to the Disease Oriented Teams (DOTs) through the bi-monthly DOT leaders meetings and to the Program Leaders at their bi-monthly meetings. Information flows both directions at these meetings as DOT leaders can vet investigator initiated protocol ideas and Program leaders can promote agents or molecules ready for clinical evaluation. Individual DOTs are encouraged to develop and refine protocol concepts responsive to the Cancer Center priorities and to seek feedback from the Associate Director for Clinical Research early in the development process.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA142543-04
Application #
8519969
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
4
Fiscal Year
2013
Total Cost
$40,504
Indirect Cost
$27,466
Name
University of Texas Sw Medical Center Dallas
Department
Type
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Rashdan, Sawsan; Minna, John D; Gerber, David E (2018) Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy. Lancet Respir Med 6:472-478
Wijayatunge, Ranjula; Holmstrom, Sam R; Foley, Samantha B et al. (2018) Deficiency of the Endocytic Protein Hip1 Leads to Decreased Gdpd3 Expression, Low Phosphocholine, and Kypholordosis. Mol Cell Biol 38:
Hamann, Heidi A; Shen, Megan J; Thomas, Anna J et al. (2018) Development and Preliminary Psychometric Evaluation of a Patient-Reported Outcome Measure for Lung Cancer Stigma: The Lung Cancer Stigma Inventory (LCSI). Stigma Health 3:195-203
Miyata, Naoteru; Morris, Lindsey L; Chen, Qing et al. (2018) Microbial Sensing by Intestinal Myeloid Cells Controls Carcinogenesis and Epithelial Differentiation. Cell Rep 24:2342-2355
Mokdad, Ali A; Xie, Xian-Jin; Zhu, Hong et al. (2018) Statistical justification of expansion cohorts in phase 1 cancer trials. Cancer 124:3339-3345
Murphy, Caitlin C; Singal, Amit G; Baron, John A et al. (2018) Decrease in Incidence of Young-Onset Colorectal Cancer Before Recent Increase. Gastroenterology 155:1716-1719.e4
Barnes, Arti; Betts, Andrea C; Borton, Eric K et al. (2018) Cervical cancer screening among HIV-infected women in an urban, United States safety-net healthcare system. AIDS 32:1861-1870
Murphy, Caitlin C; Fullington, Hannah M; Alvarez, Carlos A et al. (2018) Polypharmacy and patterns of prescription medication use among cancer survivors. Cancer 124:2850-2857
McMillan, Elizabeth A; Ryu, Myung-Jeom; Diep, Caroline H et al. (2018) Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. Cell 173:864-878.e29
Zhang, Shuyuan; Nguyen, Liem H; Zhou, Kejin et al. (2018) Knockdown of Anillin Actin Binding Protein Blocks Cytokinesis in Hepatocytes and Reduces Liver Tumor Development in Mice Without Affecting Regeneration. Gastroenterology 154:1421-1434

Showing the most recent 10 out of 501 publications